Has Rachael Grace received payments from drug or device companies?

Yes. Drug and device makers reported $200,874 in general payments to Rachael Grace across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rachael Grace did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rachael Grace come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rachael Grace

Pediatric Hematology-Oncology · Boston, MANPI 1144335100

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Agios Pharmaceuticals, Inc. accounts for 80.3% of it on its own, with 6 other manufacturers making up the rest. Among pediatric hematology-oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$200,874in general payments, 2019–2025

Across 60 payments — averaging $3347.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Agios Pharmaceuticals, Inc.$161K
Swedish Orphan Biovitrum AB$23K
Novartis$5K
Sanofi$4K
Sanofi US Services Inc.$3K
Dova Pharmaceuticals$3K
plus $1K from 1 others

$4,071,214in research payments, 2019–2025

Across 196 payments — averaging $20,771 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Agios Pharmaceuticals, Inc.$2.4M
Novartis$1.3M
Sobi, Inc$333K
Dova Pharmaceuticals$33K
Pfizer$3K

What the payments were for

Consulting fees$113,70357%
Speaking & faculty fees$39,94420%
Travel & lodging$46,72823%
Food & beverage$4990%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Agios Pharmaceuticals, Inc.	49	$161,210
Swedish Orphan Biovitrum AB	3	$22,555
Novartis	1	$5,440
Sanofi	1	$3,740
Sanofi US Services Inc.	1	$3,364
Dova Pharmaceuticals	3	$3,110
Sobi, Inc	2	$1,455

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

PYRUKYND$58,601
PROMACTA$5,440
DOPTELET$4,455

How this compares

$200,874 in reported general payments places this provider in the 95th percentile of 114 pediatric hematology-oncology providers in Massachusetts.

See all pediatric hematology-oncology providers in Massachusetts →

Other pediatric hematology-oncology in Boston

Leslie KeanBoston$558K
Todd GolubBoston$213K
Stacy CroteauBoston$117K
Matthew HeeneyBoston$101K
Susan PerrineBoston$96K
Christine DuncanBoston$89K
Eric GrabowskiBoston$56K
Derek HansonBoston$54K
Susan ParsonsBoston$47K
Karen BrideBoston$47K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →